Zymeworks Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 28.71 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.04B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Details
| Name | Zymeworks Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 231 |
| Founded | 2003 |
| Ipo Date | 2017-04-28 |
| Ceo | Kenneth Galbraith |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US98985Y1082 |
| Cusip | 98985Y108 |
| Cik | 0001937653 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Kenneth H. Galbraith C.A. | Chairman of the Board, Chief Executive Officer and President |
| Dr. Paul A. Moore Ph.D. | Chief Scientific Officer |
| Scott Platshon B.S. | Executive Vice President and Chief Business Officer |
| Kristin Stafford C.P.A. | Executive Vice President and Chief Financial Officer |
| Mark Hollywood | Executive Vice President and Chief Operating Officer |
Contact
| Address | 108 Patriot Drive, Suite A, Middletown, Delaware 19709, United States |
| Phone | 302 274 8744 |
| Website | https://www.zymeworks.com |